CASIF (CASIF) Stock Price & Analysis
CASIF (CASIF) closed at USD 0.1 on Friday, October 23, 2026, up 0.15% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 0.1; the Oct 23, 2026 session ranged USD 0.1–0.1 on volume of 1,600 shares. Market capitalization is —, with a 52-week range of USD 0.05–1.77 (OQB). Source: Nexqual, retrieved October 24, 2026 at 01:37 UTC.
Also available as compact Markdown for AI agents: nexqual.com/CASIF.md
Key facts (CASIF)
- Total return with dividends: 1Y -93.9% vs S&P 500 +13.4%; 5Y -99.1% vs S&P 500 +76.9%.
Total return (dividends reinvested) (CASIF)
| 1Y (from 2025-10-24) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | -93.9% | -99.1% |
| S&P 500 (SPY) | +13.4% | +76.9% |
| Per year | -94.0% | -60.8% |
| Volatility (annualized) | 225.1% | 110.2% |
| Max drawdown | -93.9% (Oct 2025→Jun 2026) | -99.1% (Nov 2021→Oct 2026) |
CASIF suppliers, customers and competitors (named in its 20-F)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Supplier | Spectrum Pharmaceuticals | “We had a supply agreement with Spectrum to support our application for import drug registration and for commercialization purposes.” |
| Supplier | Resources Pharmaceutical Commercial Group International Trading | “We rely on one single distributor, CRPCGIT for the distribution of EVOMELA® and CNMC for the distribution of FOLOTYN®.” |
| Supplier | China National Medicines Corporation | “We rely on one single distributor, CRPCGIT for the distribution of EVOMELA® and CNMC for the distribution of FOLOTYN®.” |
| Partner | Acrotech Biopharma | “In July 2023, we entered into a tripartite assignment agreement with Mundipharma International Corporation Limited ("MICL"), Mundipharma Medical Company ("MMCo") and Acrotech, pursuant to which, MICL's rights and obligations under that certain License, Development and Commercialization Agreement (as amended and restated) dated as of May 29, 2013 for the commercialization of FOLOTYN® (Pralatrexate) in China, with c…” |
| Partner | Mundipharma International Corporation | “In July 2023, we entered into a tripartite assignment agreement with Mundipharma International Corporation Limited ("MICL"), Mundipharma Medical Company ("MMCo") and Acrotech, pursuant to which, MICL's rights and obligations under that certain License, Development and Commercialization Agreement (as amended and restated) dated as of May 29, 2013 for the commercialization of FOLOTYN® (Pralatrexate) in China, with c…” |
| Partner | Guangzhou Gloria Biosciences | “In January 2025, we entered into a three-year distribution agreement with Guangzhou Gloria Biosciences Co., Ltd., pursuant to which CASI China was appointed as a non-exclusive distributor for the sales of YuTuo® in China.” |
| Partner | ETP Global III Fund | “On December 11, 2025, we entered into a convertible note purchase agreement (the "Purchase Agreement") with ETP Global III Fund LP, a partnership controlled by Dr. Wei-Wu He (the "Purchaser"), pursuant to which the Company would issue and sell convertible notes in an aggregate principal amount of US $20 million to the Purchaser through a private placement transaction.” |
| Partner | Cleave Therapeutics | “On July 18, 2023, we entered into an assignment agreement with Cleave, pursuant to which we obtained the global intellectual property rights related to CB-5339.” |
| Partner | Juventas Cell Therapy | “CNCT19 is an autologous CD19 CAR-T investigative product (CNCT19) being developed by our partner Juventas for which we have exclusive worldwide co-commercial and profit-sharing rights.” |
| Partner | Precision Autoimmune Therapeutics | “Other operating income for the year ended December 31, 2023, were US$6.4 million, mainly consisted of a US$4.4 million reimbursement from PAT for certain labor cost and certain pre-clinical and clinical service incurred in previous years, a US$1.3 million refund from Pharmathen Global BV with respect to the termination of the exclusive distribution license agreement of product Octreotide LAI, and a US$0.6 million …” |
| Partner | Human Longevity | “In December 2024, we entered into a service agreement with Human Longevity Inc. ("HLI"), pursuant to which CASI will use certain of HLI's office facilities at a service charge of $8,000 per month.” |
Quoted from the company's 20-F filed May 15, 2026.
Key Statistics (as of October 24, 2026 at 01:37 UTC)
| Price | USD 0.1 |
|---|---|
| Change | ▲ 0.15% (up) |
| Previous Close | USD 0.1 |
| Open | USD 0.1 |
| Day Range | USD 0.1 – 0.1 |
| 52-Week Range | USD 0.05 – 1.77 |
| Volume | 1,600 shares |
| Market Cap | — |
| Exchange | OQB |
Technical Analysis (CASIF)
Nexqual's technical model rates CASIF "SELL" based on 1 bullish and 5 bearish signals across 127 daily candles, as of October 24, 2026 at 01:37 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 35.02 (neutral) |
| vs SMA50 | Below (USD 0.13) |
| MACD | -0.01 (negative) |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CRIS | Curis, Inc. | USD 0.39 | ▼ 3.43% |
| BGMSP | Bio Green Med Solution Inc. | USD 2.55 | ▲ 6.36% |
| AGEN | Agenus Inc. | USD 6.33 | ▼ 2.76% |
| BIOM | Biomolecular Life Holdings, Inc | USD 0.91 | ▼ 0% |
| CERS | Cerus Corporation | USD 2.33 | ▲ 0.87% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 24, 2026 at 01:37 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt